Author:
Aredo Jacqueline V,Wakelee Heather A,Neal Joel W,Padda Sukhmani K
Reference21 articles.
1. F. Investigators, Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer;Soria;N Engl J Med,2018
2. Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A Review;Piper-Vallillo;J Clin Oncol,2020
3. Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations;Janjigian;Cancer Discov,2014
4. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both;Katakami;J Clin Oncol,2013
5. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial;Miller;Lancet Oncol,2012
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献